Literature DB >> 10976414

The use of a combined regimen of GnRH agonist plus a low-dose oral contraceptive improves the spontaneous pulsatile LH secretory characteristics in patients with polycycstic ovary disease after discontinuation of treatment.

A D Genazzani1, C Battaglia, O Gamba, F Petraglia, B Malavasi, A R Genazzani.   

Abstract

PURPOSE: The fertility rate in women with polycystic ovary disease (PCOD) is influenced by the type of treatment received. The present study evaluated the possible correlation between treatment and pulsatile release of gonadotropins.
METHODS: Spontaneous episodic secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) and hormonal parameters were monitored before and after 1, 3, and 6 months after treatments suspension. Twenty-four PCOD patients were randomly divided into two groups of 12 subjects. Group A was treated with gonadotropin-releasing hormone (GnRH)-analogue plus oral contraceptive (OC). Group B was treated only with OC. Both groups were treated for 6 months and followed up for 6 months.
RESULTS: In all subjects the therapeutic regimens reduced the androgenic milieau and the gonadotropin plasma levels. Spontaneous pulsatile secretion of LH and FSH was significantly modified in both groups, but patients who received the combined regimen showed a significantly greater reduction of LH plasma levels and a significantly greater decrease of LH pulse amplitude throughout the 6 months after treatment suspension. Ferriman-Gallway score and ovarian volumes were significantly reduced in patients who received the combined treatment than in the OC-treated patients.
CONCLUSIONS: These data support the evidence of a higher efficacy of the combination of GnRH-a + OC than OC alone in restoring a normal and adequate spontaneous episodic gonadotropin discharge and in decreasing Ferriman-Gallway score and ovarian volumes in patients with PCOD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10976414      PMCID: PMC3455206          DOI: 10.1023/a:1009410416638

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  31 in total

1.  Comparison of a gonadotropin-releasing hormone agonist and a low dose oral contraceptive given alone or together in the treatment of hirsutism.

Authors:  J S Heiner; G A Greendale; A K Kawakami; P S Lapolt; M Fisher; D Young; H L Judd
Journal:  J Clin Endocrinol Metab       Date:  1995-12       Impact factor: 5.958

2.  The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome.

Authors:  A Dunaif; D Scott; D Finegood; B Quintana; R Whitcomb
Journal:  J Clin Endocrinol Metab       Date:  1996-09       Impact factor: 5.958

3.  Finasteride in the treatment of hirsutism: new therapeutic perspectives.

Authors:  A Tolino; A Petrone; F Sarnacchiaro; D Cirillo; S Ronsini; G Lombardi; C Nappi
Journal:  Fertil Steril       Date:  1996-07       Impact factor: 7.329

4.  Clinical and endocrine effects of finasteride, a 5 alpha-reductase inhibitor, in women with idiopathic hirsutism.

Authors:  L Ciotta; A Cianci; A E Calogero; M A Palumbo; E Marletta; A Sciuto; G Palumbo
Journal:  Fertil Steril       Date:  1995-08       Impact factor: 7.329

5.  Oral contraceptive pills, gonadotropin-releasing hormone agonists, or use in combination for treatment of hirsutism: a clinical research center study.

Authors:  B R Carr; N A Breslau; C Givens; W Byrd; C Barnett-Hamm; P B Marshburn
Journal:  J Clin Endocrinol Metab       Date:  1995-04       Impact factor: 5.958

6.  Prolonged treatment of hirsutism with flutamide alone in patients affected by polycystic ovary syndrome.

Authors:  E Pucci; A D Genazzani; F Monzani; F Lippi; F Angelini; M Gargani; D Barletta; M Luisi; A R Genazzani
Journal:  Gynecol Endocrinol       Date:  1995-09       Impact factor: 2.260

7.  Clinical and hormonal effects of gonadotropin-releasing hormone agonist plus an oral contraceptive in severely hirsute patients with polycystic ovary disease.

Authors:  L Ciotta; A Cianci; G Giuffrida; E Marletta; A Aglianò; G Palumbo
Journal:  Fertil Steril       Date:  1996-01       Impact factor: 7.329

8.  Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome.

Authors:  J E Nestler; D J Jakubowicz
Journal:  N Engl J Med       Date:  1996-08-29       Impact factor: 91.245

9.  Long-term GnRH-agonist administration revealed a GnRH-independent mechanism stimulating FSH discharge in humans.

Authors:  A D Genazzani; F Massolo; E Ferrari; A Gandolfi; F Petraglia; A R Genazzani
Journal:  Eur J Endocrinol       Date:  1996-01       Impact factor: 6.664

10.  Leuprolide and estrogen versus oral contraceptive pills for the treatment of hirsutism: a prospective randomized study.

Authors:  R Azziz; T M Ochoa; E L Bradley; H D Potter; L R Boots
Journal:  J Clin Endocrinol Metab       Date:  1995-12       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.